Edition:
United States

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

23.80USD
16 Feb 2018
Change (% chg)

$-0.10 (-0.42%)
Prev Close
$23.90
Open
$23.80
Day's High
$24.40
Day's Low
$23.60
Volume
130,765
Avg. Vol
207,959
52-wk High
$24.75
52-wk Low
$12.70

Latest Key Developments (Source: Significant Developments)

Heron Therapeutics Says Enrollment Complete In Both Pivotal Phase 3 Studies For Htx-011
Monday, 8 Jan 2018 08:30am EST 

Jan 8 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS - ENROLLMENT COMPLETE IN BOTH PIVOTAL PHASE 3 STUDIES FOR HTX-011; TOP-LINE RESULTS EXPECTED IN H1 OF 2018.HERON THERAPEUTICS INC - FOR PHASE 3 EFFICACY STUDIES IN BUNIONECTOMY AND HERNIA REPAIR, EXPECTS TO FILE AN NDA WITH FDA IN H2 OF 2018.  Full Article

Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock
Tuesday, 5 Dec 2017 09:00am EST 

Dec 5 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF SHARES OF ITS COMMON STOCK​.  Full Article

Heron Therapeutics Announces Public Offering Of Common Stock
Monday, 4 Dec 2017 04:01pm EST 

Dec 4 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - INTENDS TO USE PROCEEDS FROM PROPOSED SALE OF ITS SHARES OF COMMON STOCK FOR GENERAL CORPORATE PURPOSES.  Full Article

Heron Therapeutics gets FDA approval for Cinvanti
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Heron Therapeutics Inc :Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv).U.S. Commercial launch of Cinvanti is planned for January 2018​.Remain on-track with htx-011 which we expect to file for FDA review in 2018​.  Full Article

Heron Therapeutics reports qtrly diluted net loss per share $0.77
Monday, 6 Nov 2017 08:30am EST 

Nov 6 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Qtrly basic and diluted net loss per share $0.77‍​.Heron Therapeutics Inc - ‍net product sales of Sustol for three months ended September 30, 2017 were $8.6 million​.Heron Therapeutics Inc - ‍Heron's cash, cash equivalents and short-term investments were $74.0 million as of September 30, 2017​.Heron Therapeutics Inc - ‍guidance for full-year 2017 net product sales of Sustol remains $25 million to $30 million​.  Full Article

Heron Therapeutics granted FDA fast track designation for HTX-011
Thursday, 26 Oct 2017 08:30am EDT 

Oct 26 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours.Heron Therapeutics Inc - ‍Phase 3 studies for HTX-011 ongoing; NDA filing planned for 2018​.Heron Therapeutics - ‍expect to report top-line results from pivotal phase 3 studies in first half of 2018 and file for FDA review in second half of 2018​.  Full Article

Heron Therapeutics reports quarterly loss per share $0.80
Wednesday, 9 Aug 2017 04:20pm EDT 

Aug 10 (Reuters) - Heron Therapeutics Inc -:Heron Therapeutics reports financial results for the three and six months ended June 30, 2017 and recent corporate progress.Quarterly loss per share $0.80.Heron Therapeutics Inc - ‍has increased its full year 2017 net product sales of sustol guidance to a range of $25 to $30 million​.Heron - ‍believes cash, cash equivalents and short-term investments provides co with funding sufficient to complete htx-011 phase 3 studies in h1 2018​.  Full Article

Heron Therapeutics initiates phase 3 program for HTX-011
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics announces initiation of phase 3 program for HTX-011 in postoperative pain following successful end-of-phase 2 meeting with FDA.‍Phase 3 program expected to enable broad indication​.‍NDA filing planned for 2018​.‍FDA noted beyond agreed-upon phase 3 studies,no additional clinical work needed to meet "combination rule" for fixed-dose combination products​.  Full Article

Heron Therapeutics reports quarterly loss per share $1.00
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Heron Therapeutics Inc : :Heron Therapeutics reports financial results for the three months ended March 31, 2017 and recent corporate progress.Quarterly loss per share $1.00.  Full Article

Heron Therapeutics appoints Robert Hoffman as CFO
Monday, 24 Apr 2017 04:05pm EDT 

April 24 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics appoints Robert E. Hoffman as chief financial officer and senior vice president, finance.Heron Therapeutics Inc - prior to joining Heron, Hoffman served as executive vice president and chief financial officer of Innovus Pharmaceuticals.  Full Article